Access Pharmaceuticals Inc. (AMEX:AKC)


Novel platinum-polymer delivery system designed to deliver high concentrations of chemotherapeutic agents directly to solid tumors

Colorectal cancer

A Phase I study is progressing in Europe (5/10)

Antisoma plc (UK; LSE:ASM)

Pemtumomab (formerly Theragyn)

Murine monoclonal antibody HMFGI, and chemical linker that binds to yttrium-90; targets polymorphic epithelial mucin (PEM), an abnormal form of mucine produced by tumor cells of the epithelium

Ovarian cancer

Europe granted orphan drug status to Pemtumomab (5/31)

FeRx Inc.*

MTC- Doxorubicin

Delivered with MTC technology

Primary liver cancer

Company received approval in China to conduct a Phase II study (5/22)

Ontogen Corp.*


Used in combination with intravenous paclitaxel; oral drug


Company began a Phase I study in Canada (5/3)

Oxigene Inc. (OXGN)


Combretastastin A-4 prodrug; vascular targeting agent that attacks blood vessels that support a tumor


Phase I data from its UK trial showed CA4P can be administered at safe, effective doses; data presented at ASCO (5/14)

Oxxon Pharmaccines Ltd. (UK)*


Therapy involves sequential immunization, using different vectors to deliver the same antigen, aiming to elicit a T-cell response


Company began Phase I trials (5/29)

Zeltia-PharmaMar (Spain; MSE:ZELTIA)

Ecteinascidin 743 (ET-743)

Marine compound obtained from the tunicate Ecteinascidia turbinata, or the sea squirt

Soft-tissue sarcoma

Phase II results presented at ASCO showed ET-743 shrunk some tumors and controlled disease for prolonged periods with acceptable tolerability in patients (5/14)


Chiron Corp. (CHIR)


Recombinant human interferon beta-1b

Relapsing- remitting multiple sclerosis

An independent study in Italy suggested that Betaseron reduced signs of disease activity more effectively than Avonex (5/8)

KS Biomedix Holdings plc (UK; LSE:KSB)


Small molecule that modulates biochemical imbalances

Rheumatoid arthritis

Company received approval to begin a European Phase IIb trial (5/11)


Amylin Pharmaceuticals Inc. (AMLN)


Pramlintide acetate; analogue of human amylin, a hormone secreted with insulin by the beta cells in the pancreas

Type I or Type II diabetes

Company submitted marketing authorization applications in Europe (5/31)


Gilead Sciences Inc. (GILD)

Tenofovir disoproxil fumarate

Reverse transcriptase inhibitor


Company submitted a marketing authorization application in Europe (5/4)

ICN Pharmaceuticals Inc. (NYSE:ICN)


Capsules for use in combination with interferon alfa-2b injection (Intron A)

Chronic hepatitis C

Schering-Plough K.K. submitted an NDA in Japan (5/8)

SciClone Pharmaceuticals Inc. (SCLN)


Immune system enhancer; synthetic immunostimulant peptide

Chronic hepatitis B

Results from a study conducted in Turkey showed significantly greater response rates in patients treated with a combination of Zadaxin and alpha interferon than those treated with alpha interferon alone (5/21)


Atrix Laboratories Inc. (ATRX)


Combines the Atrigel drug delivery system with the antibiotic doxycycline

Periodontal disease

Atrix received approval in Germany, Denmark and Sweden to market Atridox (5/3)

Curis Inc. (CRIS) and Stryker Corp. (NYSE:SYK)

OP-1 Implant

Osteogenic protein 1

Nonunion of the tibia

European Commission granted marketing authorization (5/17)

International Wex Technologies Inc. (Canada; CDNX:WXI)


Non-narcotic pharmaceutical developed from a naturally occurring organic substance

Drug addiction

Company began a Phase I trial (5/2)

NexMed Inc. (NEXM)


Cream treatment that incorporates alprostadil with NexMed's NexACT transdermal penetration enhancing technology

Erectile dysfunction

Company said an NDA was filed in Hong Kong (5/3)

Protein Polymer Technologies Inc. (PPTI) and Femcare Ltd. (UK)*

Urethral bulking agent (UBA)

Formulation containing a silk-elastin polymer, designed for use as an injectable UBA

Female stress urinary incontinence

Femcare received clearance to initiate clinical trials in the UK (5/1)

SciClone Pharmaceuticals Inc. (SCLN)


Intended to repair protein associated defect in CFTR protein

Cystic fibrosis

Company was granted orphan drug status in Europe for CPX (5/22)


* Denotes privately held company.

ASCO = The 37th Annual Meeting of the American Society for Clinical Oncology.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; MSE = Madrid Stock Exchange; NYSE = New York Stock Exchange

NDA = New Drug Application

No Comments